2 results
Approved WMORecruiting
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
Approved WMOPending
1. Does exercise training improve muscle function and exercise tolerance in patients with IPAH?2. Does exercise training in IPAH result in morphological and biochemical changes of the quadriceps muscle?3. Does exercise training in IPAH result in…